Rivaroxaban - Percutaneous Coronary Intervention

Bursa Postgraduate Hospital

Status: Completed

Conditions: Coronary Artery Disease; Atrial Fibrillation

Treatments: Drug: In vitro heparin

Study type: Observational

Funder types: Other

Identifiers

NCT05541757

BYİEAH4

Details and patient eligibility

About

We investigated in-vitro the management of intraprocedural anticoagulation in patients requiring immediate percutaneous coronary intervention(PCI) while using regular direct oral anticoagulants(DOACs). Twenty-five patients taking 20mg of rivaroxaban once daily comprised the study group, while five healthy volunteers included the control group. In study group, a beginning(24-hours after the last rivaroxaban dose) examination was performed. Then, the effects of basal and four different anticoagulant doses(50IU/kg unfractionated heparin(UFH), 100IU/kg UFH, 0.5mg/kg enoxaparin, and 1mg/kg enoxaparin) on coagulation parameters were investigated at the 4th and 12th hours following rivaroxaban intake. Anticoagulant activity was assessed mainly by anti-factor Xa(anti-Xa) levels.

Enrollment: 30 patients

Sex: All

Ages: 18 to 74 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients using the direct oral factor Xa inhibitor rivaroxaban
• Atrial fibrillation

Exclusion criteria

• malignancy,
• coagulopathy,
• heart valve disease,
• active infection,
• chronic systemic or inflammatory disease,
• recent ACS or elective PCI,
• uncontrolled hypertension and diabetes,
• cerebrovascular accident,
• thyroid disorder,
• left ventricular systolic dysfunction (ejection fraction <50%),
• glomerular filtration rate <50 mL/min/1.73 m2,
• underweight and overweight (<60 kg and >100 kg),
• age >75 years,
• hyperbilirubinemia and hypertriglyceridemia (>350 mg/dl).

Trial design

30 participants in 2 patient groups

control group

Description:

five healthy adults

Treatment:

Drug: In vitro heparin

Study group

Description:

Twenty-five patients using the direct oral factor Xa inhibitor rivaroxaban

Treatment:

Drug: In vitro heparin